Trump Announces 100% Tariff on Branded Drugs, Exempts U.S.‑Built Pharmaceutical Factories
CompanyDrug

Trump Announces 100% Tariff on Branded Drugs, Exempts U.S.‑Built Pharmaceutical Factories

China Unveils National Long‑Term Care Insurance Service Catalog in Pilot Phase
Policy / Regulatory

China Unveils National Long‑Term Care Insurance Service Catalog in Pilot Phase

Sichuan Biokin Secures Second Breakthrough Therapy Designation for Izalontamab Brengitecan in Advanced Urothelial Carcinoma
CompanyDrug

Sichuan Biokin Secures Second Breakthrough Therapy Designation for Izalontamab Brengitecan in Advanced Urothelial Carcinoma

Fosun Pharma’s Alovatinib Enters China’s Pediatric Anti‑Tumor SPARK Pilot
CompanyDrug

Fosun Pharma’s Alovatinib Enters China’s Pediatric Anti‑Tumor SPARK Pilot

Eli Lilly Halts Obesity Study of Experimental Drug Bimagrumab for Strategic Reasons
CompanyDrug

Eli Lilly Halts Obesity Study of Experimental Drug Bimagrumab for Strategic Reasons

Sanofi Injects an Extra USD 625 Million into Sanofi Ventures to Boost Biotech & Digital‑Health Innovation
CompanyDeals

Sanofi Injects an Extra USD 625 Million into Sanofi Ventures to Boost Biotech & Digital‑Health Innovation

Illumina Partners with Pharma Giants on Pan‑Cancer Companion Diagnostics Using TruSight Oncology
CompanyDeals

Illumina Partners with Pharma Giants on Pan‑Cancer Companion Diagnostics Using TruSight Oncology

AstraZeneca and Daiichi Sankyo Submit Priority‑Review sBLA for Enhertu as First‑Line Therapy for HER2‑Positive Breast Cancer
CompanyDrug

AstraZeneca and Daiichi Sankyo Submit Priority‑Review sBLA for Enhertu as First‑Line Therapy for HER2‑Positive Breast Cancer

Gan Lee Secures 3 B RMB Supply Deal for Insulin Glargine in Brazil’s National PDP
CompanyDeals

Gan & Lee Secures 3 B RMB Supply Deal for Insulin Glargine in Brazil’s National PDP

MicroTech Medical Secures NMPA Approval for Equil Patch Insulin Pump in Children and Adolescents
CompanyMedical Device

MicroTech Medical Secures NMPA Approval for Equil Patch Insulin Pump in Children and Adolescents

Biogen Receives FDA Complete‑Response Letter on High‑Dose Nusinersen for SMA
CompanyDrug

Biogen Receives FDA Complete‑Response Letter on High‑Dose Nusinersen for SMA

Eisai and Biogen Secure Australian TGA Approval for Lecanemab in Early Alzheimer’s Disease
CompanyDrug

Eisai and Biogen Secure Australian TGA Approval for Lecanemab in Early Alzheimer’s Disease